Feature
Deal Tracker
Significant pharma deals - M&A, licensing, formulary contracts, biosimilar arrangements, and value-based agreements. Updated continuously.
Filter:
69 deals
Specialty Pharma
Undisclosed
Metformin Hydrochloride · Antidiabetic (Biguanide)
Yichang Humanwell’s approval for generic metformin tablets marks another global player’s entry into the high-demand diabetes treatment segment.
Jun 3, 2024
closed
Specialty Pharma
Undisclosed
Darifenacin Hydrobromide · Urinary antispasmodic
This approval reinforces Aurobindo’s expansion into urology-focused generics, addressing overactive bladder therapies at lower cost.
Jun 1, 2024
closed
Specialty Pharma
Undisclosed
Levetiracetam · Antiepileptic
XGen’s entry into the generic epilepsy medication space strengthens competition and patient access to affordable antiepileptic options.
Jun 1, 2024
closed
Specialty Pharma
Undisclosed
Buprenorphine Hydrochloride · Opioid dependence treatment
Actavis’s approval for generic buprenorphine boosts access to key opioid addiction therapies, supporting broader treatment availability.
May 31, 2024
closed
Specialty Pharma
Undisclosed
Emtricitabine · Antiretroviral (HIV)
Aurobindo Pharma expands its HIV portfolio in the U.S. generics market, increasing competition and lowering treatment costs.
May 31, 2024
closed
M&A
Undisclosed
This acquisition expands Biogen’s presence in ophthalmology and complement biology, adding Apellis’s marketed and pipeline assets including treatments for geographic atrophy.
May 1, 2026
closed
M&A
Undisclosed
The acquisition expands IMG Pharma’s footprint in the Japanese market and strengthens its product development capabilities across key therapy areas.
May 9, 2026
announced
M&A
Undisclosed
Chiesi Group’s acquisition of KalVista expands its portfolio in rare diseases, particularly in hereditary angioedema, strengthening its specialty medicine presence.
Apr 29, 2026
announced
M&A
$4.1B
The acquisition gives Angelini Pharma a strong foothold in the U.S. rare neurological disease market and expands its global presence.
May 13, 2026
announced
M&A
Undisclosed
Replay gene therapy platform · gene therapy / dermatology
This deal strengthens LEO Pharma’s focus on rare skin diseases by integrating Replay’s gene therapy platform, potentially enabling new treatment modalities for genetic dermatological conditions.
Apr 30, 2026
announced
M&A
Undisclosed
The merger of Suven Pharma and Cohance aims to consolidate India’s contract development and manufacturing capabilities (CDMO), creating a scaled player in the specialty pharma and CDMO sectors.
Apr 29, 2026
pending
M&A
$2.2B
bispecific T-cell engager platform · autoimmune biologics
UCB’s acquisition of Candid strengthens its pipeline in autoimmune diseases through access to Candid’s bispecific T-cell engager technology, marking a strategic expansion into next-generation immunotherapies.
May 1, 2026
announced
M&A
Undisclosed
Italy’s Angelini Group is reportedly exploring a potential acquisition of Catalyst Pharmaceuticals, signaling growing European interest in U.S. rare disease assets.
Apr 26, 2026
pending
M&A
Undisclosed
Telomir closed an all-stock deal for TELI Pharmaceuticals, issuing 34.4 million shares to expand its portfolio in longevity-related therapeutics.
Apr 22, 2026
closed
M&A
$7B
in vivo CAR-T platform · cell therapy / oncology
The acquisition strengthens Lilly’s push into gene and cell therapy, expanding its in vivo CAR-T development capabilities in oncology and other therapeutic areas.
Apr 20, 2026
announced
M&A
$300M
This acquisition allows Lilly to strengthen its pipeline in the promising field of antibody-drug conjugates, which are gaining traction in targeted cancer therapies.
Mar 1, 2023
announced
M&A
Undisclosed
This acquisition enhances BioMarin's rare disease portfolio, potentially increasing its market share in this niche therapeutic area.
Mar 1, 2023
announced
M&A
Undisclosed
LSL Pharma's acquisitions are aimed at doubling their revenue, indicating a strategic expansion to strengthen their market position.
announced
M&A
Undisclosed
This acquisition by Royalty Pharma is significant as it could enhance their portfolio and increase their market influence in the pharmaceutical industry.
closed
M&A
$430M
The termination of this acquisition highlights potential challenges in the merger process, which could impact future consolidation strategies in the industry.
announced
Licensing
Undisclosed
Madrigal drug
The deal targets a promising drug from Madrigal, potentially accelerating its development and commercialization through Teva's extensive network.
announced
Licensing
$15M
Hypercon™ Technology
This deal leverages Halozyme's drug delivery technology to potentially enhance Vertex's product offerings, showcasing the importance of advanced delivery systems in pharma.
announced
M&A
$6.5B
Metsera · obesity
Novo's counteroffer indicates strong interest in the obesity treatment sector, highlighting the competitive landscape for innovative weight management therapies.
pending
M&A
$6B
This acquisition will enhance Merck's oncology portfolio, potentially strengthening its position in the cancer treatment market.
pending
M&A
$5.6B
Biogen's acquisition of Apellis could strengthen its position in the immunology sector, expanding its therapeutic offerings and potentially boosting its R&D capabilities.
announced
Licensing
Undisclosed
Glycan-Targeting ADC · Antibody-drug conjugate
This global license agreement could enhance OBI Pharma's oncology pipeline by adding an innovative ADC targeting glycans, a promising area in cancer treatment.
announced
Licensing
Undisclosed
Clobetasol Propionate Ophthalmic Suspension · Ophthalmic anti-inflammatory
This agreement allows Formosa Pharmaceuticals to commercialize a specialized ophthalmic treatment, potentially filling a niche in the market for eye inflammation therapies.
announced
Licensing
Undisclosed
Innovative drug
The exclusive license agreement aims to advance the global commercialization of a new drug, potentially enhancing Gan & Lee's product offerings and market reach.
announced
M&A
Undisclosed
This acquisition could expand Pharma Fusion's retail pharmacy presence and enhance its distribution capabilities.
announced
M&A
$12B
This acquisition represents one of the largest cross-border deals by an Indian pharmaceutical company, potentially enhancing Sun Pharma's global footprint and product portfolio.
pending
Other
Undisclosed
Generic Portfolio · Multi-category
Cost Plus Drugs launches hospital formulary program offering at-cost generics plus 15% margin. Partners with 3 health systems for pilot.
announced
Specialty Pharma
$3.2B
Xiaflex/Supprelin LA · Multi-specialty
Post-bankruptcy Endo emerges with slimmed specialty portfolio. Retains Xiaflex franchise and divests 4 non-core brands to reduce debt.
pending
Specialty Pharma
$400M
Xhance (fluticasone) · ENT/Specialty
Optinose sells US commercial rights to Xhance to reduce cash burn. Buyer gets established specialty product with $180M peak sales and growing share.
announced
GPO
$580M
Specialty Generics Portfolio · Specialty/Generics
HealthTrust launches direct-from-manufacturer specialty generic program. Bypasses traditional wholesale channel for 23 high-cost specialty molecules.
announced
GPO
$1.2B
Multi-biosimilar Portfolio · Biosimilar
Premier commits member hospitals to 65% biosimilar utilization targets across 12 therapeutic categories. Largest GPO biosimilar commitment to date.
closed
GPO
$340M
Carboplatin/Cisplatin Supply · Oncology/Generics
Vizient signs 3-year committed volume contract with 4 generic manufacturers to stabilize oncology drug supply. Response to 2023 shortage crisis.
closed
Value-Based
Undisclosed
Mounjaro (tirzepatide) · Obesity/Diabetes
First GLP-1 value-based contract tied to A1C targets AND weight loss milestones. Sets precedent for outcomes-based obesity drug pricing.
announced
Value-Based
Undisclosed
Repatha (evolocumab) · Cardiovascular/PCSK9
Outcomes contract links Repatha net price to LDL-C reduction targets and CV event rates. Covers 1.8M BCBS members across 12 state plans.
closed
Value-Based
Undisclosed
Entresto (sacubitril/valsartan) · Cardiovascular/Heart Failure
Pay-for-performance contract ties Entresto rebates to 30-day heart failure readmission rates. First major outcomes-based deal for an ARNI.
closed
Biosimilar
Undisclosed
SB17 (ustekinumab) · Immunology/Biosimilar
First ustekinumab biosimilar filed with FDA. $10B Stelara market opens to competition. Could launch in 2026 following J&J patent settlement.
pending
Biosimilar
Undisclosed
Mvasi (bevacizumab-awwb) · Oncology/Biosimilar
Fresenius Kabi biosimilar reaches 38% market share in oncology infusion centers. Driven by 340B spread opportunity and GPO contracting.
closed
Biosimilar
$30/vial
Insulin Glargine/Lispro/Aspart · Diabetes/Biosimilar
Mark Cuban-backed Civica launches 3 insulin biosimilars at $30/vial. Undercuts branded insulins by 90%. Available through hospital GPOs and direct.
closed
Biosimilar
Undisclosed
Hyrimoz (adalimumab-adaz) · Immunology/Biosimilar
First adalimumab biosimilar granted interchangeable status by FDA. Allows automatic pharmacy substitution in all 50 states without prescriber approval.
closed
Formulary
Undisclosed
Multiple GLP-1s · Obesity/Diabetes
Express Scripts excludes 3 branded GLP-1 products from 2026 national preferred formulary. Steers 2.4M members to preferred alternatives.
announced
Formulary
Undisclosed
Multi-product · Specialty Pharma
OptumRx collapses 3 specialty tiers into 2 for 2026 formulary year. Moves 47 products to preferred specialty tier with lower copays.
announced
Formulary
Undisclosed
Wegovy (semaglutide) · Obesity/GLP-1
ESI adds Wegovy to standard commercial formularies after negotiating undisclosed rebate. First major PBM to broadly cover GLP-1 for obesity.
closed
Formulary
Undisclosed
Hadlima (adalimumab-bwwd) · Biosimilar/Immunology
CVS Caremark names Hadlima as sole preferred Humira biosimilar across commercial formularies. Blocks 7 competing biosimilars from preferred tier.
closed
Licensing
$284M
OV329 (soticlestat) · Neuroscience/Epilepsy
Takeda licenses first-in-class cholesterol 24-hydroxylase inhibitor for rare epilepsies. Fills gap in Takeda neuro pipeline after Alzheimer exits.
closed
Licensing
$8.4B
BL-B01D1 · Oncology/ADC
Bristol Myers licenses bispecific EGFR x HER3 ADC from Chinese biotech. Largest outbound China biotech licensing deal. Phase 3 in NSCLC underway.
announced
Licensing
$3.5B
Domvanalimab/Zimberelimab · Oncology/Immuno-Oncology
Gilead acquires remaining rights to anti-TIGIT and anti-PD-1 programs. Bet on next-generation checkpoint combinations beyond current PD-1 standard.
closed
Licensing
$1.2B
Tirzepatide (Mounjaro) · Obesity/Diabetes
CTTQ Pharma gets exclusive China rights to tirzepatide. Largest China licensing deal for a GLP-1 compound. Includes T2D and obesity indications.
closed
Licensing
$22B
DXd ADC Platform · Oncology/ADC
Largest licensing deal in pharma history. Merck gets co-development and co-commercialization rights to 3 DXd-based ADC candidates.
closed
M&A
$850M
PRX-004/PRX-005 · Ophthalmology/Bispecific
Bispecific antibodies for retinal diseases. Adds two clinical candidates targeting VEGF-A and ANG-2 simultaneously.
announced
M&A
$1.2B
FasTCAR Platform · Cell Therapy/CAR-T
Adds next-gen CAR-T platform with same-day manufacturing. Positions AZ in cell therapy with 3 clinical-stage programs in hematology.
closed
M&A
$2.7B
CT-388/CT-996 · Obesity/GLP-1
Roche enters GLP-1 obesity race with oral and injectable candidates. CT-388 is a dual GLP-1/GIP agonist competing with tirzepatide.
closed
M&A
$10.8B
PRA023 · Immunology/IBD
Adds TL1A-targeting antibody for ulcerative colitis and Crohns. Validates TL1A as next major immunology target after IL-23.
closed
M&A
$14B
KarXT (xanomeline-trospium) · CNS/Schizophrenia
First novel mechanism for schizophrenia in decades. KarXT targets muscarinic receptors, avoiding dopamine pathway side effects.
closed
M&A
$16.5B
Fill-Finish Capacity · CDMO/Manufacturing
Secures critical manufacturing capacity for GLP-1 supply chain. Addresses global semaglutide shortage by adding 3 fill-finish sites.
closed
M&A
$27.8B
Tepezza/Krystexxa · Rare Disease
Adds two blockbuster rare disease assets. FTC settlement required Amgen to maintain Horizon rebate practices for 15 years.
closed
M&A
$10.1B
Elahere (mirvetuximab) · Oncology/ADC
Adds first-in-class ADC for FRa-positive platinum-resistant ovarian cancer. Strengthens AbbVie oncology pipeline post-Humira LOE.
closed
M&A
$43B
Seagen Portfolio · Oncology/ADC
Largest pharma deal of 2023. Gives Pfizer a dominant position in antibody-drug conjugates with Adcetris, Padcev, and Tukysa.
closed
Licensing
$5.5B upfront + milestones
ADC technology platform · Oncology / ADC
Pfizer secures rights to next-gen ADC linker-payload technology. Third major ADC deal in 18 months as class dominates oncology pipeline.
announced
M&A
$14.6B
Caplyta (lumateperone) · CNS / Bipolar Depression
J&J pays 54x trailing revenue for Caplyta franchise. Expands CNS portfolio after Spravato success. EV/revenue premium signals bidding war.
closed
GPO
$4.2B annual volume
Specialty pharmacy services · Multi-class specialty
Vizient awards three-year specialty pharmacy contract covering 500+ health systems. White bagging provisions included.
closed
Value-Based
Outcomes-linked pricing
Mounjaro/Zepbound (tirzepatide) · Obesity / GLP-1
First major PBM outcomes-based contract for GLP-1 class. Rebates tied to A1C reduction and weight loss thresholds.
announced
Biosimilar
Undisclosed
ABP 654 (ustekinumab biosimilar) · Immunology / IL-12/23
Amgen files BLA for Stelara biosimilar. $10B reference product. Market entry expected Q3 2025 pending litigation settlement.
pending
Formulary
Undisclosed rebate terms
Multiple branded drugs · Multi-class
96 drugs excluded from standard formulary. Largest PBM exclusion list to date, affecting specialty and branded generics.
closed
Licensing
$2.7B total deal value
CT-388 (oral GLP-1/GIP) · Obesity / Metabolic
Roche grants Novo rights to oral dual agonist. Signals desperation to defend obesity franchise against oral competitors.
announced
M&A
$8.7B
Emraclidine (M4 agonist) · CNS / Schizophrenia
AbbVie expands CNS pipeline with novel muscarinic receptor agonist for schizophrenia. Premium of 73% to unaffected share price.
closed
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.